$IMMU - On our trading list, they are down after hours on an stock offering announcement. If you have it, gotta tough it out. If you don't this could be an opportunity to buy.Immunomedics announces $250M common stock offeringImmunomedics announced it has commenced an underwritten public offering of $250M of shares of its common stock. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform, continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs, BofA Securities, Cowen and Company, and Jefferies are acting as joint book-running managers for the offering. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page